Premium
COVID‐19 vaccination in pediatric solid organ transplant recipients—Current state and future directions
Author(s) -
L’Huillier Arnaud G.,
Ardura Monica I.,
Chaudhuri Abanti,
DanzigerIsakov Lara,
Dulek Daniel,
Green Michael,
Michaels Marian G.,
PosfayBarbe Klara M.,
Vàsquez Luciola,
Benden Christian
Publication year - 2021
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.14031
Subject(s) - medicine , immunogenicity , vaccination , pandemic , clinical trial , intensive care medicine , population , transplantation , immunization , vaccine efficacy , covid-19 , organ transplantation , immunology , pediatrics , environmental health , immune system , infectious disease (medical specialty) , disease
Abstract Background Population‐level COVID‐19 immunization will play a key role in slowing down the SARS‐CoV‐2 pandemic on a global scale and protect the most at‐risk individuals. Thanks to a formidable universal effort, several SARS‐CoV‐2 vaccines have been marketed less than a year since the first documented COVID‐19 case, with promising safety, efficacy, and immunogenicity results in adults. As children were not included in the initial trials, no vaccine is currently approved for individuals <16 years of age. Similarly, immunosuppressed individuals, such as solid organ transplant recipients, were excluded from initial vaccine trials, limiting the understanding of vaccine immunogenicity and safety in this at‐risk population. Thus, data regarding COVID‐19 vaccination in pediatric solid organ transplantation recipients are currently lacking. Methods Members of the International Pediatric Transplant Association review the current general status of COVID‐19 vaccines focusing on pediatric‐specific issues. Results This review provides an overview of COVID‐19 vaccines in pediatric SOT recipients and highlights the current paucity of data in both pediatric and transplant settings in terms of safety, immunogenicity, and clinical efficacy. Conclusions Vaccine trials including children and transplant recipients are underway and will be necessary to characterize COVID‐19 vaccine safety, immunogenicity, and efficacy, which will determine potential future research directions.